{
    "clinical_study": {
        "@rank": "30153", 
        "acronym": "CSBPM", 
        "arm_group": [
            {
                "arm_group_label": "4L-split Dose of PEG Solution", 
                "arm_group_type": "Active Comparator", 
                "description": "4L-split Dose of PEG Solution for bowel preparation"
            }, 
            {
                "arm_group_label": "Low-volume PEG Plus Ascorbic Acid", 
                "arm_group_type": "Active Comparator", 
                "description": "Low-volume PEG Plus Ascorbic Acid for bowel preparation"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy, acceptability and preparation-induced\n      mucosal inflammation of PEG + ascorbic acid vs. PEG for colonoscopy."
        }, 
        "brief_title": "The Comparative Study Between Bowel Preparation Method", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Colonoscopy", 
        "detailed_description": {
            "textblock": "This was a prospective randomized single-blinded clinical trial of ambulatory patients to\n      assess the efficacy of bowel preparation and preparation-induced mucosal inflammation.\n\n      Endoscopists who were blinded to the preparation taken, assessed both bowel cleansing by\n      using the Ottawa bowel preparation assessment tool and preparation-induced mucosal\n      inflammation. Acceptability was assessed by questionnaire."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who want colonoscopy purposing screening among adults between the age of\n             20~65\n\n        Exclusion Criteria:\n\n          -  Under the age of 20, older than 65, pregnant or lactating women, intestinal\n             obstruction, structural intestinal disease, hypothyroidism, gastrointestinal\n             motility, renal failure, congestive heart failure, liver failure, electrolyte\n             abnormalities, who refused research informed consent, inflammatory bowel disease, the\n             obvious symptoms of the disease in patients with lower gastrointestinal (bloody\n             stools, diarrhea, etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "319", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01964417", 
            "org_study_id": "PEG-0488"
        }, 
        "intervention": {
            "arm_group_label": [
                "4L-split Dose of PEG Solution", 
                "Low-volume PEG Plus Ascorbic Acid"
            ], 
            "intervention_name": "Colonoscopy after bowel cleansing", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ascorbic Acid"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "BOWEL PREPARATION", 
            "PEG", 
            "Low-volume PEG Plus Ascorbic Acid"
        ], 
        "lastchanged_date": "January 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of", 
                    "zip": "612-896"
                }, 
                "name": "Haeundae Paik Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Comparative Study Between Bowel Preparation Method: 4L-split Dose of PEG Solution, Low-volume PEG Plus Ascorbic Acid Focusing on the Bowel Cleansing Efficacy, Patients' Affinity to Preparation Solution and Mucosal Injury", 
        "overall_official": {
            "affiliation": "Inje University", 
            "last_name": "Jongha Park, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Comparison of colon cleansing between the two solutions using Ottawa scale", 
            "safety_issue": "No", 
            "time_frame": "3month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01964417"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Inje University", 
            "investigator_full_name": "Jongha Park", 
            "investigator_title": "Inje University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Inje University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Inje University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}